|Sponsor||Medivation Inc. (Prosper)|
A Phase 3 Randomized, Placebo-controlled Double-blind Study of Enzalutamide (formerly MDV3100) versus placebo in subjects with Non-Metastatic Castration-resistant Prostate Cancer (CRPC)
Determine the efficacy of enzalutamide compared with placebo as assessed by metastasis-free survival (MFS)
-Subject must be a man age ≥ 18 years of age
-Small cell or neuroendocrine carcinoma of the prostate
-Weakness, fatigue, back pain, decreased appetite, constipation, joint pain, diarrhea, hot flashes, upper respiratory tract infection, swelling in hands, arms, legs or feet, shortness of breath, muscle/bone pain, weight loss, headache, high blood pressure, dizziness or vertigo
Interested in enrolling in this trial? Please call 717-431-2285.